Reaction phenotyping in drug discovery: Moving forward with confidence?

Current Drug Metabolism

Volumn 4, Issue 6, 2003, Pages 527-534

  Williams, James Andrew ^a   Hurst, Susan I ^a   Bauman, Jonathan ^a   Jones, Barry C ^b   Hyland, Ruth ^b   Gibbs, John P ^b   Obach, R Scott ^b   Ball, Simon E ^a  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

Drug discovery; Drug metabolizing enzymes; Reaction phenotyping

Indexed keywords

ALLOPURINOL; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BENZYDAMINE; CHLORPROMAZINE; CLORGYLINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; HYDRALAZINE; MACROLIDE; MENADIONE; NEW DRUG; PARGYLINE; SELEGILINE; STEROID; SUMATRIPTAN; ZALEPLON;

ANALYTIC METHOD; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CROSS REACTIVITY; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER METABOLISM; NONHUMAN; PHENOTYPE; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; STANDARDIZATION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 0348038711     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389200033489235     Document Type: Review

References (22)

1. Banker, M.J., Clark, T.H. and Williams J.A. (2003) J. Pharm. Sci. 92(5), 967-74.
2. Obach, R.S. (1999) Drug Metab. Dispos. 27(11), 1350-9.
3. Bjornsson, T.D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, R. S., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M., Walsh, J., Wrighton, S. A. (2003) Drug Metab. Dispos. 31(7), 815-32.
4. Madan, A.J. (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Drug-Drug Interactions, Ed. A.D. Rodrigues, Marcel-Dekker, New York, 217-294.
5. Parkinson, A.J. (2000) Biotransformation, in Cassarett and Doull's Toxicology, C. Klassen, Editor.
6. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W. P., Kirchgessner, T. G. (2003) J. Biol. Chem. 52, 37161-8.
7. Ghahramani, P., Ellis, S. W., Lennard, M. S., Ramsay, L. E., Tucker, G. T. (1997) Br. J. Clin. Pharmacol. 43(2), 137-44.
8. Eagling, V.A. et al. (2002) Xenobiotica 32(1), 1-17.
9. Obach, R.S. and Reed-Hagen, A.E. (2002) Drug Metab. Dispos. 30(7), 831-7.
10. Ortiz de Montellano, P.R. and Reich, N.O. (1986) Inhibition of cytochrome P450 enzymes, in Cytochrome P-450, Ortiz de Montellano, P.R. Editor.
11. Balani, S.K., Zhu, T., Yang, T. J., Liu, Z., He, B., Lee, F. W. (2002) Drug Metab. Dispos. 30(10), 1059-62.
12. Ekins, S., Stresser, D.M. and Williams, J.A. (2003) Trends Pharmacol. Sci. 24(4), 161-6.
13. Cashman, J.R. (2002) Pharmacogenomics 3(3), 325-39.
14. Lake, B.G., Ball, S. E., Kao, J., Renwick, A. B., Price, R. J., Scatina, J. A. (2002) Xenobiotica 32(10), 835-47.
15. Beedham, C. (2002) Molybdenum hydroxylases. In: Ioannides C, ed. Enzyme Systems That Metabolise Drugs and Other Xenobiotics. New York: John Wiley & Sons, Ltd., 48-187.
16. Kalgutkar, A.S., Dalvie, D. K., Castagnoli, N. Jr., Taylor, T. J. (2001) Chem. Res. Toxicol. 14(9), 1139-62.
17. Stormer, E., Roots, I., Brockmoller, J. (2000) Br. J. Clin. Pharmacol. 50(6), 553-61.
18. Dixon, C.M., Park, G. R., Tarbit, M. H. (1994) Biochem. Pharmacol. 47(7), 1253-7.
19. Ethell, B.T., Ekins, S., Wang, J., Burchell, B. (2002) Drug Metab. Dispos. 30(6), 734-8.
20. Sorich, M.J., Smith, P. A., McKinnon, R. A., Miners, J. O. (2002) Pharmacogenetics 12(8), 635-45.
21. Goosen, T.C., Arimoto, R., Gifford, E., Ball, S.E., Hurst, S.I., Tugnait, M., Hollenberg, P.F., Williams, J.A. (2003) Drug Metab. Rev. 35, 58.
22. Court, M.H. In vitro identification of UDP-glucuronosyltransferases (UGTs) involved in drug metabolism. Optimization in Drug Discovery: In-Vitro Methods (in Press).